Doxorubicin-melphalan with and without cisplatin in advanced ovarian cancer: Ten-year survival results from a prospective randomized study by the Swedish Cooperative Ovarian Cancer Study Group

Acta Oncologica

Volumn 35, Issue SUPPL. 8, 1996, Pages 109-118

  Tropé, Claes ^a,b   Andersson, Håkan ^a   Björkholm, Elisabeth ^a   Frankendal, Bo ^a   Himmelman, Anna ^a   Högberg, Thomas ^a   Horvath, György ^a   Petterson, Birgitta ^a   Persson, Helena ^a   Ryberg, Marianne ^a   Simonsen, Ernst ^a   Sorbe, Bengt ^a   Stendahl, Ulf ^a   Westholm, Bertil ^a  

^a Department of Gynecologic Oncology ^*  (Sweden)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; MELPHALAN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASCITES; CISPLATIN; DOXORUBICIN; FEMALE; HUMANS; MELPHALAN; MIDDLE AGED; NEOPLASM, RESIDUAL; OVARIAN NEOPLASMS; PROGNOSIS; SWEDEN;

EID: 8044246579     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.3109/02841869609098528     Document Type: Article

References (38)

1. Sigurdsson K, Alm P, Gullberg B. Prognostic factors in malignant epithelial ovarian tumours. Gynecol Oncol 1983; 15: 370-80.
2. Tropé C. Melphalan with and without doxorubicin in advanced ovarian cancer. Obstet Gynecol 1987; 70: 582-6.
3. Ozols RF, Young RC. Chemotherapy of ovarian cancer. Semin Oncol 1984; 9: 251-6
4. WHO handbook for reporting results of cancer treatment. Geneva. World Health Organization 1979.
5. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-81.
6. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50: 163-70.
7. Cox DR. Regression models and life tables. J R Stat Soc Ser B 1972; 34: 187-220.
8. Tropé C, Andersson H, Friberg L, et al. Doxorubicin + Melphalan versus Doxorubicin + Melphalan + Cisplatin in a prospective randomized study in advanced ovarian cancer. XII World Congress of Gynecology and Obstetrics (FIGO), Rio de Janeiro 1988. Abs. 140.
9. Gaducci A, Bruzzone M, Carino F, Ragni N, Rubagotti A, Conte P. Twelve year follow up of a randomized trial comparing Cisplatin and Cyclophosphamide in patients with advanced epithelial cancer. Int J Cancer 1996; 6: 286-90.
10. Gruppo Interregionale Cooperativo Oncologico Ginecologia. Long-term results of a randomized trial comparing cisplatin, with cisplatin and cyclophosphamide, and cyclophosphamide with cisplatin, cyclophosphamide, and adriamycin in advanced ovarian cancer. Gynecol Oncol 1992; 45: 115-7.
11. Hoskins WJ, Bundy BN, Thigpen JT, Omura GG. The influence of cytoreductive surgery on recurrence-free interval and survival in small volume stage III epithelial ovarian cancer: A Gynecologic Oncology Group study. Gynecol Oncol 1992; 47: 159-66.
12. Nejt JP. Ovarian cancer treatment: Time for some hard thinking. Eur J Cancer 1991; 27: 680-1.
13. Friedlander ML, Dembo AJ. Prognostic factors in ovarian cancer. Semin Oncol 1991; 18: 205-12.
14. Louie KG, Ozols RF, Myers CE, et al. Long-term survival results of a cisplatin-containing combination chemotherapy regimen for the treatment of advanced ovarian carcinoma. J Clin Oncol 1986; 4: 1579-85.
15. Nejt JP, van der Burg ME, van Oosterom AT, et al. Combination chemotherapy in advanced ovarian carcinoma: the experience of The Netherlands Joint Study Group for Ovarian Cancer. In: Conte PF, Ragni N, Rosso R, Vermorken JB, eds. Multimodal Treatment of Ovarian Cancer. New York: Raven Press, 1989; 227-35.
16. Bertelsen K. Tumor reduction surgery and long-term survival in advanced ovarian cancer: A DACOVA study. Gynecol Oncol 1990; 38: 203-9.
17. Högberg T. Ovarian cancer. Treatment results, prognostic factors, and tumor marker surveillance (thesis). Linköping University, Fac of Health Sciences 1992; p 33.
18. Piver MS, Baker T. The potential for optimal (≤2 cm) cytoreductive surgery in advanced ovarian carcinoma at a tertiary medical center: A prospective study. Gynecol Oncol 1986; 24: 1-8.
19. Heintz APM, van Oosterom AT, Trimbos JBMC, Schaberg A, van der Velde EA, Nooy M. The treatment of advanced ovarian carcinoma: (I) Clinical variables associated with prognosis. Gyneol Oncol 1988; 30: 347-58.
20. Hoskins PJ, Oreilly SE, Swenerton KD, Spinelli JJ, Fairey RN, Benedet JL. 10-year outcome of patients with advanced epithelial ovarian carcinoma treated with cisplatin-based multimodality therapy. J Clin Oncol 1992; 10: 1561-8.
21. Makar A, Baekelandt M, Tropé C, Kristensen G. The prognostic significance of residual disease, FIGO substage, tumor histology and grade in patients with FIGO Stage III ovarian cancer. Gynecol Oncol 1995; 56: 175-82.
22. Hacker NF, Berek JS, Lagasse LD, Nieberg RK, Elashoff RM. Primary cytoreductive surgery for epithelial ovarian cancer. Obstet Gynecol 1983; 61: 413-20.
23. Hunter RW, Alexander NDE, Soutter WP. Meta-analysis of surgery in advanced ovarian carcinoma: Is maximum cytoreductive surgery an independent determinant of prognosis? Am J Obstet Gynecol 1992; 166: 504-11.
24. Van der Burg MEL, van Lent M, Kobierska A, et al. Intervention debulking surgery (IDS) does improve survival in advanced epithelial ovarian cancer (EOC); and EORTC gynecological cancer cooperative group (GCCG) study. ASCO May, 1993: p. 258.
25. Hoskins W, McGuire W, Brady M, et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol 1994; 170: 974-80.
26. Lippman SM, Alberts DS, Slymen DJ, et al. Second-look laparotomy in epithelial ovarian carcinoma. Cancer 1988; 61: 2571-7.
27. Podraz KZ, Malkasian GD, Wieand HS, et al. Recurrent disease after negative second-look laparotomy in stages III and IV ovarian carcinoma. Gynecol Oncol 1988; 29: 274-82.
28. Nejt JP, ten Bokkel Huinink WW, van der Burg MEL, et al. Randomized trial comparing two combination chemotherapy regimens (CHAP-5v) in advanced ovarian carcinoma. J Clin Oncol 1987; 5: 1157-68.
29. Cain JM, Saigo PE, Pierce VK, et al. A review of second-look laparotomy for ovarian cancer. Gynecol Oncol 1986; 23: 14-25.
30. Sutton GP, Stehman FB, Einhorn LH, Roth LM, Blessing JA, Ehrlich CE, Ten-year follow-up of patients receiving cisplatin, doxorubicin and cyclophosphamide chemotherapy for advanced epithelial ovarian carcinoma, J Clin Oncol 1989; 7: 223-9.
31. Nejt JP, ten Bokkel Hunink WW, van der Burg MEL, et al. Long-term survival in ovarian cancer. Eur J Cancer 1991; 27: 1367-72.
32. Sorbe B, Tropé C, Nordal R, et al. Chemotherapy versus radiotherapy as consolidation treatment of ovarian carcinomas stage III at surgical complete remission from induction chemotherapy. Proc ASCO 1996; 15: 780.
33. Bertelsen K, Hansen MK, Pedersen, PH et al. The prognostic and therapeutic value of second-look laparotomy in advanced ovarian cancer. Br J Obstet Gynecol 1988; 95: 1231-6.
34. Luesley D, Blackledge G, Kelly K. Failure of second-look laparotomy to influence survival in epithelial ovarian cancer. Lancet 1988; 2: 599-603.
35. Stanhope R, Smith J, Ruthledge F. Second trial drugs in ovarian cancer. Gynecol Oncol 1977; 5: 52-5.
36. The Ovarian Cancer Meta-Analysis Group. Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin and cisplatin chemotherapy of ovarian carcinoma: a meta-analysis. J Clin Oncol 1991; 9: 1668-74.
37. A'Hern RP, Gore ME. Impact of doxorubicin on survival in advanced ovarian cancer. J Clin Oncol 1995; 13: 726-32.
38. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334: 1.